Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$235 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.7
Industry P/E
--
EV/EBITDA
-5.8
Div. Yield
0 %
Debt to Equity
-0
Book Value
$1
EPS
$-1.9
Face value
--
Shares outstanding
47,233,949
CFO
$-141.19 Mln
EBITDA
$-284.95 Mln
Net Profit
$-221.50 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Silence Therapeutics PLC (SLN)
| -4.2 | 7.1 | -4.2 | 140.7 | -2.1 | -24.0 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Silence Therapeutics PLC (SLN)
| -11.6 | -60.1 | 13.9 | -36.2 | 8.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Silence Therapeutics PLC (SLN)
|
5.8 | 235.2 | 0.6 | -88.6 | -14,555.6 | -98.3 | -- | 4.7 |
| 3.4 | 311.8 | 73.2 | -67.8 | -55.3 | -65.5 | -- | 4.1 | |
| 20.7 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.4 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.2 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 8.2 | 193.7 | 0.0 | -29.0 | -- | -20.4 | -- | 2.8 | |
| 16.8 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.4 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 6.1 | 913.1 | 174.7 | -115.2 | 0.0 | -80.2 | -- | 7.4 | |
| 20.5 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular,... and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom. Address: 12 Hammersmith Grove, London, United Kingdom, W6 7AP Read more
President, CEO & Executive Director
Mr. Craig A. Tooman M.B.A.
President, CEO & Executive Director
Mr. Craig A. Tooman M.B.A.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Silence Therapeutics PLC (SLN) is $5.55 (NASDAQ) as of 02-Apr-2026 12:35 EDT. Silence Therapeutics PLC (SLN) has given a return of -2.06% in the last 3 years.
Since, TTM earnings of Silence Therapeutics PLC (SLN) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-3.22
|
6.18
|
|
2024
|
-6.98
|
2.36
|
|
2023
|
-14.85
|
29.22
|
|
2022
|
-9.70
|
22.11
|
|
2021
|
--
|
--
|
The 52-week high and low of Silence Therapeutics PLC (SLN) are Rs 7.91 and Rs 1.97 as of 02-Apr-2026.
Silence Therapeutics PLC (SLN) has a market capitalisation of $ 235 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Silence Therapeutics PLC (SLN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.08
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.